Radiotherapy and Olaparib in Combination for Carcinoma of the Oesophagus: A Phase I Study

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2023 Mar 23

PMID 36949958

Authors

Hamid Sheikh

David Ryder

Andrew Bateman

Anthony Chalmers

Andrew Jackson

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Radical concurrent chemoradiotherapy (CRT) for oesophageal cancer is associated with significant morbidity and is unsuitable for some patients. Olaparib, an inhibitor of the DNA repair enzyme poly-(ADP)-ribose polymerase (PARP) has radiosensitising properties and may be better tolerated than chemotherapy.

Materials And Methods: We performed a phase 1 study of olaparib with radiotherapy (RT) in oesophageal cancer patients unsuitable for conventional CRT to determine its maximum tolerated dose (MTD) in this setting.

Results: Eight patients were recruited. One of 5 patients receiving olaparib 50 mg twice daily and two of 3 receiving 100 mg twice daily experienced dose limiting toxicity (DLT).

Conclusions: Olaparib 100 mg twice daily exceeded the MTD in combination with RT in these patients. 50 mg twice daily may be the MTD but this cannot be stated with certainty as the study closed before full recruitment.

Citing Articles

Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.

Xue Z, Nuerrula Y, Sitiwaerdi Y, Eli M Biomol Biomed. 2024; 24(3):545-559.

PMID: 38340316 PMC: 11088896. DOI: 10.17305/bb.2024.10184.

Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.

Brand N, Yang Y, Ding V, Dutta H, Peto C, Lemjabbar-Alaoui H Am J Cancer Res. 2024; 14(1):378-389.

PMID: 38323288 PMC: 10839305.

PARP inhibitors combined with radiotherapy: are we ready?.

Sun C, Chu A, Song R, Liu S, Chai T, Wang X Front Pharmacol. 2023; 14:1234973.

PMID: 37954854 PMC: 10637512. DOI: 10.3389/fphar.2023.1234973.

References

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

Bang Y, Im S, Lee K, Cho J, Song E, Lee K . Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol. 2015; 33(33):3858-65. DOI: 10.1200/JCO.2014.60.0320. View

Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-37. DOI: 10.1016/S1470-2045(13)70136-0. View

Kubota E, Williamson C, Ye R, Elegbede A, Peterson L, Lees-Miller S . Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014; 13(13):2129-37. PMC: 4111704. DOI: 10.4161/cc.29212. View

Lesueur P, Lequesne J, Grellard J, Dugue A, Coquan E, Brachet P . Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019; 19(1):198. PMC: 6399862. DOI: 10.1186/s12885-019-5413-y. View

Hulshof M, Geijsen E, Rozema T, Oppedijk V, Buijsen J, Neelis K . Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021; 39(25):2816-2824. DOI: 10.1200/JCO.20.03697. View

de Haan R, van den Heuvel M, van Diessen J, Peulen H, van Werkhoven E, de Langen A . Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. Clin Cancer Res. 2020; 27(5):1256-1266. DOI: 10.1158/1078-0432.CCR-20-2551. View

Cooper J, Guo M, Herskovic A, Macdonald J, Martenson Jr J, Al-Sarraf M . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17):1623-7. DOI: 10.1001/jama.281.17.1623. View

Bang Y, Xu R, Chin K, Lee K, Park S, Rha S . Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(12):1637-1651. DOI: 10.1016/S1470-2045(17)30682-4. View

10.

Karam S, Reddy K, Blatchford P, Waxweiler T, DeLouize A, Oweida A . Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018; 24(20):4949-4959. PMC: 6873707. DOI: 10.1158/1078-0432.CCR-18-0467. View

11.

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View

12.

Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S . Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clin Oncol (R Coll Radiol). 2019; 32(2):121-130. DOI: 10.1016/j.clon.2019.09.058. View

13.

Loap P, Loirat D, Berger F, Cao K, Ricci F, Jochem A . Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial. Int J Cancer. 2021; 149(10):1828-1832. DOI: 10.1002/ijc.33737. View

14.

Nguewa P, Fuertes M, Valladares B, Alonso C, Perez J . Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol. 2004; 88(1):143-72. DOI: 10.1016/j.pbiomolbio.2004.01.001. View

15.

Kim H, Kim M, Hodgson D, Harbron C, Wellings R, OConnor M . Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology. 2013; 80(3):127-37. DOI: 10.1159/000346034. View

16.

Virag L, Szabo C . The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002; 54(3):375-429. DOI: 10.1124/pr.54.3.375. View

17.

Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N . PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?. Cancers (Basel). 2021; 13(21). PMC: 8582502. DOI: 10.3390/cancers13215380. View